Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.63 USD | -2.85% | -7.27% | -20.47% |
Apr. 25 | Top Premarket Gainers | MT |
Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 126.9 | 87.88 | 84.69 | 54.16 | 71.8 | 57.61 | - | - |
Enterprise Value (EV) 1 | 126.9 | 87.88 | 84.69 | 54.16 | 71.8 | 57.61 | 57.61 | 57.61 |
P/E ratio | -2.72 x | -1.11 x | -1.57 x | -1.76 x | -3.05 x | -0.98 x | -2.31 x | -3.58 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 6.07 x | 7.28 x | 1.71 x | 0.84 x | 1.12 x | 2.39 x | 1.34 x | 1.08 x |
EV / Revenue | 6.07 x | 7.28 x | 1.71 x | 0.84 x | 1.12 x | 2.39 x | 1.34 x | 1.08 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | -0.59 x | -0.63 x | -0.6 x |
FCF Yield | - | - | - | - | - | -168% | -158% | -166% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 1,652 | 2,197 | 3,334 | 3,581 | 4,522 | 4,562 | - | - |
Reference price 2 | 76.80 | 40.00 | 25.40 | 15.13 | 15.88 | 12.63 | 12.63 | 12.63 |
Announcement Date | 3/4/20 | 2/25/21 | 3/7/22 | 3/23/23 | 4/22/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 20.92 | 12.07 | 49.57 | 64.29 | 63.9 | 24.07 | 42.86 | 53.25 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -41.72 | -71.85 | -42.26 | -29.72 | -24.48 | -63.06 | -41.59 | -33.65 |
Operating Margin | -199.49% | -595.42% | -85.24% | -46.23% | -38.31% | -261.98% | -97.05% | -63.2% |
Earnings before Tax (EBT) 1 | -41.09 | -72.11 | -42.47 | -29.53 | -22.49 | -61.8 | -40.43 | -32.98 |
Net income 1 | -41.09 | -74.87 | -42.47 | -29.8 | -22.93 | -61.8 | -40.43 | -32.98 |
Net margin | -196.47% | -620.48% | -85.67% | -46.35% | -35.88% | -256.72% | -94.33% | -61.95% |
EPS 2 | -28.20 | -36.00 | -16.20 | -8.600 | -5.200 | -12.88 | -5.470 | -3.527 |
Free Cash Flow 1 | - | - | - | - | - | -97 | -90.75 | -95.45 |
FCF margin | - | - | - | - | - | -402.97% | -211.75% | -179.26% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/4/20 | 2/25/21 | 3/7/22 | 3/23/23 | 4/22/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 7.076 | 7.225 | 7.109 | 6.216 | 40.74 | 10.22 | 25.99 | 7.614 | 12.72 | 17.58 | 9.033 | 4.233 | 5.333 | 6.338 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.04 | -16.77 | -18.26 | -13.11 | 14.92 | -13.27 | 2.977 | -12.83 | -8.555 | -3.676 | -11.33 | -16.03 | -17.17 | -17.73 |
Operating Margin | -254.89% | -232.11% | -256.87% | -210.96% | 36.63% | -129.83% | 11.45% | -168.52% | -67.27% | -20.91% | -125.46% | -378.74% | -321.88% | -279.72% |
Earnings before Tax (EBT) 1 | -18.08 | -16.8 | -18.28 | -13.12 | 14.98 | -13.1 | 3.209 | -12.21 | -7.942 | -3.149 | -11 | -15.7 | -16.87 | -17.43 |
Net income 1 | -18.08 | -16.8 | -18.28 | -13.12 | 11.9 | -13.38 | 2.532 | -12.36 | -8.172 | -3.213 | -11 | -15.7 | -16.87 | -17.43 |
Net margin | -255.55% | -232.57% | -257.15% | -211.05% | 29.2% | -130.9% | 9.74% | -162.29% | -64.26% | -18.27% | -121.77% | -370.87% | -316.25% | -274.99% |
EPS 2 | -7.400 | -5.600 | -5.400 | -3.800 | 3.400 | -3.800 | 0.6000 | -2.800 | -1.800 | -0.8000 | -2.387 | -3.363 | -3.647 | -3.297 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 3/7/22 | 5/11/22 | 8/9/22 | 11/3/22 | 3/23/23 | 5/11/23 | 8/3/23 | 11/2/23 | 4/22/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | - | - | -97 | -90.8 | -95.5 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0.04 | 0.19 | 0.04 | 0.12 | - | 0.5 | 0.5 | 0.5 |
Capex / Sales | 0.17% | 1.54% | 0.08% | 0.18% | - | 2.08% | 1.17% | 0.94% |
Announcement Date | 3/4/20 | 2/25/21 | 3/7/22 | 3/23/23 | 4/22/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.47% | 57.61M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CDTX Stock
- Financials Cidara Therapeutics, Inc.